Anti CD40 HPV vaccine - EnnoDC
Alternative Names: Anti-CD40 HPV vaccine - EnnoDC; CD40.HVac; CD40HVac; HPV anti-CD40 HPV vaccineLatest Information Update: 30 Jul 2026
At a glance
- Originator Vaccine Research Institute
- Developer EnnoDC
- Class Papillomavirus vaccines; Protein vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Human papillomavirus infections
Most Recent Events
- 02 Jun 2026 Adverse event, efficacy and immunogenicity data from a phase I/IIa trial in Human papillomavirus infections presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
- 06 Mar 2025 EnnoDC plans to initiate phase IIb trial in Human papillomavirus infections (Prevention) in Q1 2025 (Parenteral) (EnnoDC pipeline, March 2025)
- 26 Sep 2024 LinKinVax is now called EnnoDC